These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6787910)

  • 1. Antiarrhythmic efficacy of encainide and quinidine: validation of a model for drug assessment.
    Sami M; Harrison DC; Kraemer H; Houston N; Shimasaki C; DeBusk RF
    Am J Cardiol; 1981 Jul; 48(1):147-56. PubMed ID: 6787910
    [No Abstract]   [Full Text] [Related]  

  • 2. Encainide for refractory ventricular tachyarrhythmia.
    Chesnie B; Podrid P; Lown B; Raeder E
    Am J Cardiol; 1983 Sep; 52(5):495-500. PubMed ID: 6193701
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias.
    Morganroth J; Somberg JC; Pool PE; Hsu PH; Lee IK; Durkee J; Salerno DM
    J Am Coll Cardiol; 1986 Jan; 7(1):9-16. PubMed ID: 3079781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of encainide and quinidine for supraventricular tachyarrhythmias.
    Mäkynen PJ; Koskinen PJ; Saaristo TE; Liisanantti RK
    Am J Cardiol; 1988 Dec; 62(19):55L-59L. PubMed ID: 3144169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic drug combinations in the treatment of ventricular tachycardia.
    Ross DL; Sze DY; Keefe DL; Swerdlow CD; Echt DS; Griffin JC; Winkle RA; Mason JW
    Circulation; 1982 Dec; 66(6):1205-10. PubMed ID: 6814784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites.
    Anderson JL; Stewart JR; Johnson TA; Lutz JR; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(5):812-9. PubMed ID: 6182414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia.
    Toivonen L; Kadish A; Morady F
    Circulation; 1991 Jul; 84(1):101-8. PubMed ID: 1905591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia.
    Mason JW; Peters FA
    Circulation; 1981 Mar; 63(3):670-5. PubMed ID: 6780234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
    Herre JM; Titus C; Oeff M; Eldar M; Franz MR; Griffin JC; Scheinman MM
    Ann Intern Med; 1990 Nov; 113(9):671-6. PubMed ID: 2121082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide.
    Brugada P; Abdollah H; Wellens HJ
    J Am Coll Cardiol; 1984 Dec; 4(6):1255-60. PubMed ID: 6438205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response range of encainide for benign and potentially lethal ventricular arrhythmias.
    Morganroth J; Pool P; Miller R; Hsu PH; Lee I; Clark DM
    Am J Cardiol; 1986 Apr; 57(10):769-74. PubMed ID: 3083665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs.
    Slater W; Lampert S; Podrid PJ; Lown B
    Am J Cardiol; 1988 Feb; 61(4):349-53. PubMed ID: 3124591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant ventricular tachyarrhythmias associated with the use of encainide.
    Winkle RA; Mason JW; Griffin JC; Ross D
    Am Heart J; 1981 Nov; 102(5):857-64. PubMed ID: 6795909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of oral encainide in frequent and repetitive ventricular arrhythmias.
    Bongiorni MG; Levorato D; Arlotta C; Paperini L; Contini C
    Eur Heart J; 1988 Jul; 9(7):765-76. PubMed ID: 3139413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic drug therapy for sustained ventricular tachycardia.
    Kienzle MG; Williams PD; Zygmont D; Doherty JU; Josephson ME
    Heart Lung; 1984 Nov; 13(6):614-22. PubMed ID: 6149202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of ventricular preexcitation and associated arrhythmias by encainide.
    Roden DM; Duff HJ; Primm RK; Kronenberg MW; Woosley RL
    Am Heart J; 1981 Oct; 102(4):794-7. PubMed ID: 6792894
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests, and radionuclide cineangiographic studies.
    DiBianco R; Fletcher RD; Cohen AI; Gottdiener JS; Singh SN; Katz RJ; Bates HR; Sauerbrunn B
    Circulation; 1982 Jun; 65(6):1134-47. PubMed ID: 6804110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.